Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

Receptor tyrosine kinases are often aberrantly activated in human malignancies and contribute to cancer development and progression. Specific receptor tyrosine kinase inhibitors have been shown to be clinically effective therapies in subsets of cancer patients with either hematologic or solid tumors...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2008-10, Vol.14 (19), p.5941-5946
Main Authors: Toschi, Luca, Jänne, Pasi A
Format: Article
Language:English
Subjects:
Antineoplastic agents
Antineoplastic Agents - pharmacology
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Biological and medical sciences
Carcinoma, MET
Cell Line, Tumor
combination therapy
Gene Expression Regulation, Neoplastic
Hepatocyte Growth Factor
Hepatocyte Growth Factor - antagonists & inhibitors
Humans
inhibitor
Medical sciences
Models, Biological
Neoplasm Metastasis
Neoplasms - drug therapy
Neoplasms - metabolism
Neoplasms - pathology
Pharmacology. Drug treatments
Protein Binding
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Receptor tyrosine kinases are often aberrantly activated in human malignancies and contribute to cancer development and progression. Specific receptor tyrosine kinase inhibitors have been shown to be clinically effective therapies in subsets of cancer patients with either hematologic or solid tumors. Activation of the hepatocyte growth factor (HGF)/MET signaling pathway has been found to play a critical role in oncogenesis, cancer metastasis, and drug resistance. These observations have led to the development of agents that can effectively inhibit HGF/MET signaling through direct inhibition of the receptor (anti-MET antibodies), through inactivation of its ligand HGF (AMG102, L2G7), by interfering with HGF binding to MET (NK4), or by inhibiting MET kinase activity (PHA-665752 and SU11274). Moreover, the combination of anti-MET therapeutic agents with either signal transduction inhibitors (ERBB family or mTOR inhibitors) or with cytotoxic chemotherapy has been evaluated in preclinical models. These studies provide insight into the rational development of combination therapeutic strategies that can be evaluated in clinical trials. This review will discuss different strategies of MET inhibition with a specific focus on combination therapeutic approaches.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-08-0071